AstraZeneca PLC Financial Statements (AZN)
|
|
|
|
Report date
|
|
|
31.12.2021 |
22.02.2022 |
31.12.2022 |
21.02.2023 |
20.02.2024 |
|
30.09.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
37 417 |
37 417 |
44 351 |
44 351 |
45 811 |
|
52 120 |
|
Operating Income, bln rub |
|
|
1 056 |
1 056 |
3 757 |
3 757 |
8 193 |
|
11 031 |
|
EBITDA, bln rub |
? |
|
7 565 |
4 675 |
9 327 |
8 649 |
12 977 |
|
16 846 |
|
Net profit, bln rub |
? |
|
112.0 |
112.0 |
3 288 |
3 288 |
5 955 |
|
7 462 |
|
|
OCF, bln rub |
? |
|
5 963 |
5 963 |
9 808 |
9 808 |
10 345 |
|
12 358 |
|
CAPEX, bln rub |
? |
|
2 200 |
2 200 |
2 571 |
2 571 |
3 778 |
|
4 299 |
|
FCF, bln rub |
? |
|
3 763 |
3 763 |
7 237 |
7 237 |
6 567 |
|
8 059 |
|
Dividend payout, bln rub
|
|
|
3 856 |
3 856 |
4 364 |
4 364 |
4 481 |
|
4 643 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
3 443% |
3 443% |
132.7% |
132.7% |
75.2% |
|
62.2% |
|
|
OPEX, bln rub |
|
|
23 924 |
23 924 |
28 203 |
28 203 |
29 578 |
|
28 575 |
|
Cost of production, bln rub |
|
|
12 437 |
12 437 |
12 391 |
12 391 |
8 268 |
|
12 514 |
|
R&D, bln rub |
|
|
9 736 |
9 736 |
9 762 |
9 762 |
11 015 |
|
11 566 |
|
Interest expenses, bln rub |
|
|
1 300 |
1 300 |
1 346 |
1 346 |
1 589 |
|
1 756 |
|
|
Assets, bln rub |
|
|
105 363 |
105 363 |
96 483 |
96 483 |
101 119 |
|
104 922 |
|
Net Assets, bln rub |
? |
|
39 268 |
39 268 |
37 037 |
37 037 |
39 143 |
|
40 719 |
|
Debt, bln rub |
|
|
30 781 |
30 781 |
29 232 |
29 232 |
28 622 |
|
31 562 |
|
Cash, bln rub |
|
|
6 398 |
6 398 |
6 405 |
6 405 |
5 860 |
|
4 930 |
|
Net debt, bln rub |
|
|
24 383 |
24 383 |
22 827 |
22 827 |
22 762 |
|
26 632 |
|
|
Ordinary share price, rub |
|
|
58.3 |
58.3 |
67.8 |
67.8 |
67.4 |
|
64.3 |
|
Number of ordinary shares, mln |
|
|
2 836 |
2 836 |
3 096 |
3 096 |
3 098 |
|
3 100 |
|
|
Market cap, bln rub |
|
|
165 197 |
165 197 |
209 909 |
209 909 |
208 650 |
|
199 330 |
|
EV, bln rub |
? |
|
189 580 |
189 580 |
232 736 |
232 736 |
231 412 |
|
225 962 |
|
Book value, bln rub |
|
|
-23 116 |
-23 116 |
-22 090 |
-22 090 |
-18 994 |
|
-19 814 |
|
|
EPS, rub |
? |
|
0.04 |
0.04 |
1.06 |
1.06 |
1.92 |
|
2.41 |
|
FCF/share, rub |
|
|
1.33 |
1.33 |
2.34 |
2.34 |
2.12 |
|
2.60 |
|
BV/share, rub |
|
|
-8.15 |
-8.15 |
-7.14 |
-7.14 |
-6.13 |
|
-6.39 |
|
|
EBITDA margin, % |
? |
|
20.2% |
12.5% |
21.0% |
19.5% |
28.3% |
|
32.3% |
|
Net margin, % |
? |
|
0.30% |
0.30% |
7.41% |
7.41% |
13.0% |
|
14.3% |
|
FCF yield, % |
? |
|
2.28% |
2.28% |
3.45% |
3.45% |
3.15% |
|
4.04% |
|
ROE, % |
? |
|
0.29% |
0.29% |
8.88% |
8.88% |
15.2% |
|
18.3% |
|
ROA, % |
? |
|
0.11% |
0.11% |
3.41% |
3.41% |
5.89% |
|
7.11% |
|
|
P/E |
? |
|
1 475 |
1 475 |
63.8 |
63.8 |
35.0 |
|
26.7 |
|
P/FCF |
|
|
43.9 |
43.9 |
29.0 |
29.0 |
31.8 |
|
24.7 |
|
P/S |
? |
|
4.42 |
4.42 |
4.73 |
4.73 |
4.55 |
|
3.82 |
|
P/BV |
? |
|
-7.15 |
-7.15 |
-9.50 |
-9.50 |
-11.0 |
|
-10.1 |
|
EV/EBITDA |
? |
|
25.1 |
40.6 |
25.0 |
26.9 |
17.8 |
|
13.4 |
|
Debt/EBITDA |
|
|
3.22 |
5.22 |
2.45 |
2.64 |
1.75 |
|
1.58 |
|
|
R&D/CAPEX, % |
|
|
442.5% |
442.5% |
379.7% |
379.7% |
291.6% |
|
269.0% |
|
|
CAPEX/Revenue, % |
|
|
5.88% |
5.88% |
5.80% |
5.80% |
8.25% |
|
8.25% |
|
| AstraZeneca PLC shareholders |
